Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Exelixis

            Deal Size: Undisclosed Upfront Cash: $11.0 million

            Deal Type: Collaboration February 01, 2021

            Details:

            Exelixis will utilize Adagene’s proprietary SAFEbody™ technology to develop novel masked antibody-drug conjugates (ADCs) with potential for improved therapeutic index.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATG-022

            Therapeutic Area: Oncology Product Name: ATG-022

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Antengene

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 01, 2021

            Details:

            WuXi Biologics and WuXi STA will provide services for the process development, scale-up, and GMP manufacturing of ADC drug intermediates. Antengene will focus on the discovery of the monoclonal antibody, the core element of ADCs which includes ATG-022.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Arcus Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 09, 2020

            Details:

            Under the terms of the Strategic collaboration, parties will discover anti-CD39 antibodies using WuXi Bio’s proprietary technology. This CD39 collaboration represents the fourth antibody development program on which the two companies have joined forces.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TUB-010

            Therapeutic Area: Oncology Product Name: TUB-010

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Tubulis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership December 02, 2020

            Details:

            WuXi Biologics and WuXi STA will perform scale-up, process development and GMP manufacturing for the ADC product intermediates. The first program from Tubulis’ pipeline the companies will collaborate on is TUB-010.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HG030

            Therapeutic Area: Oncology Product Name: HG030

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Guangzhou Baiyunshan Pharmaceutical Holdings

            Deal Size: Undisclosed Upfront Cash: $5.8 million

            Deal Type: Licensing Agreement November 10, 2020

            Details:

            Baiyunshan will get exclusive rights to develop and market HG030 in mainland China, and will pay HitGen an upfront licensing fee and a series of milestones and royalty of sales as the product progresses through clinical trials and launches in the mainland China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: CMB International

            Deal Size: $142.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing September 24, 2020

            Details:

            Project Integrum aims at developing, and bringing to market novel therapeutic antibody candidates for difficult druggable targets. Biocytogen's Pipeline includes, RenMab-based target knockout mice, customized target humanized mouse models and gene therapy platforms.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 7×21 CAR-T cells

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 17, 2020

            Details:

            Study results indicated the 7×21 CAR-T cells significantly outperformed the conventional CAR-T cells in cell proliferation and chemotaxis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TJ-CD4B

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 12, 2020

            Details:

            The pre-clinical validation of TJ-CD4B/ABL111 to be presented at AACR signifies the overall progress of I-Mab’s bispecific antibody portfolio, reflecting Company’s discovery and CMC capabilities to engineer novel molecules with combined target specificities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): APG-3526

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            Ascentage Pharma will report six research results involving multiple cancer types in poster presentations during the meeting. Among them, APG-3526, the company's newest drug candidate, will be presented for the first time.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anti-SIRP-alpha antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Alector

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 26, 2020

            Details:

            Under the agreement, Innovent will lead the development and commercialization of the molecule in China, including the manufacturing of the product.

            PharmaCompass